Literature DB >> 28210558

Bisphosphonate-related osteonecrosis of jaws in advanced stage breast cancer was detected from bone scan: a case report.

Prakasit Chirappapha1, Saowanee Kitudomrat1, Thanaporn Thongjood2, Rangsima Aroonroch3.   

Abstract

Bisphosphonates (BPs) are indicated to treat skeletal-related events (SREs) for cancer patients with bone metastasis. We report a 79-year-old woman with advanced stage breast cancer with bone metastasis who was prescribed BPs (zoledronate), then developed osteonecrosis of jaw. We provide a brief review of the pathogenesis, diagnosis and treatment of this complication.

Entities:  

Keywords:  Breast cancer; bisphosphonate complication; bone metastasis; osteonecrosis of jaws

Year:  2017        PMID： 28210558      PMCID： PMC5293650          DOI： 10.21037/gs.2016.07.04

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


  50 in total

1.  Early surgical laser-assisted management of bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long-term follow-up.

Authors:  Paolo Vescovi; Maddalena Manfredi; Elisabetta Merigo; Rebecca Guidotti; Marco Meleti; Giuseppe Pedrazzi; Carlo Fornaini; Mauro Bonanini; Teore Ferri; Samir Nammour
Journal:  Photomed Laser Surg       Date:  2011-11-04       Impact factor: 2.796

2.  Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw.

Authors:  S Bocanegra-Pérez; M Vicente-Barrero; M Knezevic; J M Castellano-Navarro; E Rodríguez-Bocanegra; J Rodríguez-Millares; D Pérez-Plasencia; A Ramos-Macías
Journal:  Int J Oral Maxillofac Surg       Date:  2012-05-28       Impact factor: 2.789

3.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

4.  Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.

Authors:  Sylvie Delanian; Raphaël Porcher; Jérémie Rudant; Jean-Louis Lefaix
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

5.  Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series.

Authors:  Matthew S Epstein; Fredrick W Wicknick; Joel B Epstein; James R Berenson; Meir Gorsky
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-11

6.  Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

Authors:  Estee P Wang; Leonard B Kaban; Gordon J Strewler; Noopur Raje; Maria J Troulis
Journal:  J Oral Maxillofac Surg       Date:  2007-07       Impact factor: 1.895

7.  Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy.

Authors:  G Favia; G P Pilolli; E Maiorano
Journal:  Bone       Date:  2009-05-18       Impact factor: 4.398

8.  Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.

Authors:  Sedat Cetiner; Gulsan Turkoz Sucak; Sevil Altundag Kahraman; Sahika Zeynep Aki; Benay Kocakahyaoglu; Sibel Elif Gultekin; Mustafa Cetiner; Rauf Haznedar
Journal:  J Bone Miner Metab       Date:  2009-02-26       Impact factor: 2.626

9.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

10.  RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects.

Authors:  C Di Nisio; V L Zizzari; S Zara; M Falconi; G Teti; G Tetè; A Nori; V Zavaglia; A Cataldi
Journal:  Eur J Histochem       Date:  2015-02-03       Impact factor: 3.188
View more
  2 in total

1.  Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC.

Authors:  Sang Shin Lee; Soung Min Kim; Yeon Sook Kim; Suk Keun Lee
Journal:  PeerJ       Date:  2020-05-21       Impact factor: 2.984

2.  Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.

Authors:  Alexander Wick; Philipp Bankosegger; Sven Otto; Bettina Hohlweg-Majert; Timm Steiner; Florian Probst; Oliver Ristow; Christoph Pautke
Journal:  Clin Oral Investig       Date:  2021-11-23       Impact factor: 3.573
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.